Endocrine Abstracts

Background: Patient engagement and adherence are critical to the success of clinical trials. Electronic patient-reported outcomes (ePROs) are increasingly used to evaluate diabetes clinical trial endpoints. This study characterized how subjects prefer to use various types of technology to report ePROs in a clinical trial. Considering patient preference during diabetes trial design may reduce patient burden and improve patient engagement.Methods: 102 subj...

Background: Electronic patient-reported outcomes (ePROs) are a reliable method for collecting patient data in diabetes clinical trials and offer many advantages over paper collection; however, it is essential to consider patient preference and ease of use when employing this technology. Improving the usability of ePRO in clinical trials could ultimately reduce subject burden and improve subject engagement.Methods: 102 subjects with type 2 diabetes were s...

Introduction: Sphingosine-1-phosphate lyase (SGPL1) catalyses the final step in sphingolipid metabolism, irreversibly degrading the lipid signalling molecule sphingosine-1-phosphate (S1P). The relative abundance of S1P compared to its precursors sphingosine and ceramide finely tunes signal transduction for a wide range of cellular pathways including proliferation, apoptosis, migration and calcium handling. Loss-of-function mutations in SGPL1 cause a spectrum of disorders, incl...